620 related articles for article (PubMed ID: 34882830)
1. Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
Li J; Zheng C; Ge Q; Yan S; Paranjpe MD; Hu S; Zhou Y;
J Neurosci Res; 2022 Feb; 100(2):670-680. PubMed ID: 34882830
[TBL] [Abstract][Full Text] [Related]
2. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
[TBL] [Abstract][Full Text] [Related]
3. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease.
Yan S; Zheng C; Paranjpe MD; Li J; Benzinger TLS; Lu J; Zhou Y
Theranostics; 2020; 10(23):10563-10572. PubMed ID: 32929366
[TBL] [Abstract][Full Text] [Related]
4. Quantitative
Zhao Q; Liu M; Ha L; Zhou Y;
Front Neurol; 2019; 10():486. PubMed ID: 31156534
[TBL] [Abstract][Full Text] [Related]
5. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
[TBL] [Abstract][Full Text] [Related]
6. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
King-Robson J; Wilson H; Politis M;
J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
[TBL] [Abstract][Full Text] [Related]
7. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
8. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
9. Tau PET in Alzheimer disease and mild cognitive impairment.
Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
[TBL] [Abstract][Full Text] [Related]
10. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
11. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
12. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
13. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
14. Associations between quantitative [
Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
[TBL] [Abstract][Full Text] [Related]
15. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.
Devous MD; Fleisher AS; Pontecorvo MJ; Lu M; Siderowf A; Navitsky M; Kennedy I; Southekal S; Harris TS; Mintun MA
J Alzheimers Dis; 2021; 80(3):1091-1104. PubMed ID: 33682705
[TBL] [Abstract][Full Text] [Related]
16. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
[TBL] [Abstract][Full Text] [Related]
17. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.
Paranjpe MD; Chen X; Liu M; Paranjpe I; Leal JP; Wang R; Pomper MG; Wong DF; Benzinger TLS; Zhou Y;
Neuroimage Clin; 2019; 22():101795. PubMed ID: 30991617
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.
Das SR; Xie L; Wisse LEM; Ittyerah R; Tustison NJ; Dickerson BC; Yushkevich PA; Wolk DA;
Neurobiol Aging; 2018 Jun; 66():49-58. PubMed ID: 29518752
[TBL] [Abstract][Full Text] [Related]
19. Predicting diagnosis and cognition with
Mattsson N; Insel PS; Donohue M; Jögi J; Ossenkoppele R; Olsson T; Schöll M; Smith R; Hansson O
Alzheimers Dement; 2019 Apr; 15(4):570-580. PubMed ID: 30639421
[TBL] [Abstract][Full Text] [Related]
20. Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [
Young CB; Landau SM; Harrison TM; Poston KL; Mormino EC;
Neuroimage; 2021 Nov; 243():118553. PubMed ID: 34487825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
